Page last updated: 2024-12-11

bacteriochlorophylls

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bacteriochlorophyll A: A specific bacteriochlorophyll that is similar in structure to chlorophyll a. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

bacteriochlorophyll : Chlorophylls of photosynthetic bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bacteriochlorophylls: Pyrrole containing pigments found in photosynthetic bacteria. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11953947
MeSH IDM0002133
PubMed CID6440857
SCHEMBL ID578885
MeSH IDM0002133

Synonyms (12)

Synonym
17499-98-8
bacteriochlorophyll a
C11242 ,
bacteriochlorophyll from rhodopseudomonas sphaeroides
bacteriochlorophyll
magnesium;methyl (3r,11r,12r,21s,22s)-16-acetyl-11-ethyl-12,17,21,26-tetramethyl-4-oxo-22-[3-oxo-3-[(e,7r,11r)-3,7,11,15-tetramethylhexadec-2-enoxy]propyl]-23,25-diaza-7,24-diazanidahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1(23),2(6),5(26),8,10(2
bacteriochlorophylls
einecs 241-507-9
magnesium, ((2e,7r,11r)-3,7,11,15-tetramethyl-2-hexadecenyl (3s,4s,13r,14r,21r)-9-acetyl-14-ethyl-13,14-dihydro-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoato(2-)-kappan23,kappan24,kappan25,kappan26)-, (sp-4-2)-
magnesium, (3,7,11,15-tetramethyl-2-hexadecenyl 9-acetyl-14-ethyl-13,14-dihydro-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoato(2-)-n23,n24,n25,n26)-, (sp-4-2-(3s-(3alpha(2e,7s*,11s*),4beta,13beta,14alpha,21beta)))-
SCHEMBL578885
J-011053

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were no serious adverse events, and continence and potency were maintained."( Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
Appu, S; Aprikian, A; Bogaards, A; Elhilali, M; Evans, A; Gertner, MR; Haider, MA; McCluskey, SA; Savard, J; Scherz, A; Trachtenberg, J; Weersink, RA; Wilson, BC; Yue, C, 2007
)
0.34
"Tookad vascular targeted photodynamic therapy salvage therapy is safe and well tolerated."( Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
Appu, S; Aprikian, A; Bogaards, A; Elhilali, M; Evans, A; Gertner, MR; Haider, MA; McCluskey, SA; Savard, J; Scherz, A; Trachtenberg, J; Weersink, RA; Wilson, BC; Yue, C, 2007
)
0.34

Pharmacokinetics

ExcerptReferenceRelevance
" The main objective of the studies presented herein was to evaluate the efficacy, toxicity and pharmacokinetic profile of Photobac in animals (mice, rats and dogs) and submit these results to the United States Food and Drug Administration (US FDA) for its approval to initiate Phase I human clinical trials of glioblastoma, a deadly cancer disease with no long term cure."( Photobac derived from bacteriochlorophyll-a shows potential for treating brain tumor in animal models by photodynamic therapy with desired pharmacokinetics and limited toxicity in rats and dogs.
Bshara, W; Cacaccio, J; Curtin, L; Dukh, M; Durrani, FA; Pandey, RK; Sexton, S; Spernyak, JA; Turowski, SG, 2023
)
0.91
" This study was designed to determine if the method of photosensitizer evaluation influences the accuracy of pharmacokinetic results."( 13(2)-hydroxy-bacteriopheophorbide a methyl ester pharmacokinetics measurements with fluorescence versus absorption spectroscopy. Is there a difference?
Berlien, HP; Dressler, C; Ismail, MS; Röder, B, 1998
)
0.3
"The method of photosensitizer evaluation affects the accuracy of its pharmacokinetic results."( 13(2)-hydroxy-bacteriopheophorbide a methyl ester pharmacokinetics measurements with fluorescence versus absorption spectroscopy. Is there a difference?
Berlien, HP; Dressler, C; Ismail, MS; Röder, B, 1998
)
0.3
" The main objective of the studies presented herein was to evaluate the efficacy, toxicity and pharmacokinetic profile of Photobac in animals (mice, rats and dogs) and submit these results to the United States Food and Drug Administration (US FDA) for its approval to initiate Phase I human clinical trials of glioblastoma, a deadly cancer disease with no long term cure."( Photobac derived from bacteriochlorophyll-a shows potential for treating brain tumor in animal models by photodynamic therapy with desired pharmacokinetics and limited toxicity in rats and dogs.
Bshara, W; Cacaccio, J; Curtin, L; Dukh, M; Durrani, FA; Pandey, RK; Sexton, S; Spernyak, JA; Turowski, SG, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Thus, the tumour growth inhibition effect of HT can be substantially enhanced by combination with Bchl-ser-PDT."( Water-filtered infrared-A radiation: a novel technique for localized hyperthermia in combination with bacteriochlorophyll-based photodynamic therapy.
Kelleher, DK; Rzeznik, J; Salomon, Y; Scherz, A; Thews, O; Vaupel, P,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Monte Carlo simulations of the population PK dataset (NONMEM) were performed to select series of dosing regimen which would result in a plateau of concentration lasting at least 30 min and allow laser illumination."( Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre, MA; Ficheux, H; Fuseau, E, 2007
)
0.34
"To evaluate the 6-month effects of the recommended drug and light dosage in focal vascular-targeted photodynamic therapy (VTP) using TOOKAD(®) Soluble in patients with localized prostate cancer (LPCa)."( TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
Allen, C; Azzouzi, AR; Barret, E; Bennet, J; Coleman, J; Emberton, M; Moore, C; Muir, G; Scherz, A; Taneja, S; Villers, A, 2015
)
0.42
" To study dosing parameters and associated treatment effects we performed a prospective, multicenter, phase I/II trial of WST11 vascular targeted photodynamic therapy of prostate cancer."( Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Andriole, G; Azzouzi, AR; Bennett, J; Coleman, J; Emberton, M; Grubb, R; Marks, L; Reiter, RE; Taneja, SS, 2016
)
0.43
" Light energy, fiber number and WST11 dose were escalated to identify optimal dosing parameters for vascular targeted photodynamic therapy hemi-ablation."( Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Andriole, G; Azzouzi, AR; Bennett, J; Coleman, J; Emberton, M; Grubb, R; Marks, L; Reiter, RE; Taneja, SS, 2016
)
0.43
"After dose escalation 21 men received optimized dosing of 4 mg/kg WST11 at 200 J energy."( Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Andriole, G; Azzouzi, AR; Bennett, J; Coleman, J; Emberton, M; Grubb, R; Marks, L; Reiter, RE; Taneja, SS, 2016
)
0.43
" Dosing parameters and the light dose index appear related to tissue response as determined by magnetic resonance imaging and biopsy."( Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Andriole, G; Azzouzi, AR; Bennett, J; Coleman, J; Emberton, M; Grubb, R; Marks, L; Reiter, RE; Taneja, SS, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
bacteriochlorophyllChlorophylls of photosynthetic bacteria.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (1,626)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990364 (22.39)18.7374
1990's256 (15.74)18.2507
2000's435 (26.75)29.6817
2010's465 (28.60)24.3611
2020's106 (6.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.54 (24.57)
Research Supply Index7.33 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index80.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials11 (0.73%)5.53%
Reviews7 (2.50%)6.00%
Reviews68 (4.50%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (0.13%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other273 (97.50%)84.16%
Other1,430 (94.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]